Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests: